Results 121 to 130 of about 675 (153)
Advances in the management of erythropoietic protoporphyria – role of afamelanotide
The Application of Clinical Genetics, 2016 Erythropoietic protoporphyria (EPP) and the phenotypically similar disease X-linked protoporphyria (XLPP) are inherited cutaneous porphyrias characterized clinically by acute non-blistering photosensitivity, intolerance to sunlight, and significantly reduced quality of life.
Herbert L Bonkovsky
exaly +6 more sources
Clinical and dermoscopic changes of acquired melanocytic nevi of patients treated with afamelanotide [PDF]
Photochemical and Photobiological Sciences, 2021 AbstractBackgroundAfamelanotide (AFA) is a synthetic analogue of α-melanocyte-stimulating hormone that is approved for the treatment of patients affected by erythropoietic protoporphyria (EPP). AFA induces a “sun free” tanning and changes of acquired melanocytic nevi (AMN) that are generically described as “darkening”.ObjectivesTo assess clinical and ...
Mariachiara Arisi, Pg Calzavara-Pinton
exaly +3 more sources
Afamelanotide and Narrowband UV-B Phototherapy for the Treatment of Vitiligo [PDF]
JAMA Dermatology, 2015 Narrowband UV-B (NB-UV-B) phototherapy is used extensively to treat vitiligo. Afamelanotide, an analogue of α-melanocyte-stimulating hormone, is known to induce tanning of the skin.To evaluate the efficacy and safety of combination therapy for generalized vitiligo consisting of afamelanotide implant and NB-UV-B phototherapy.This study was performed in ...
Henry W Lim +2 more
exaly +3 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Afamelanotide: A Review in Erythropoietic Protoporphyria
American Journal of Clinical Dermatology, 2016Afamelanotide (SCENESSE(®)) is a synthetic α-melanocyte stimulating hormone analogue and first-in-class melanocortin-1 receptor agonist that is approved in the EU for the prevention of phototoxicity in adults with erythropoietic protoporphyria (EPP). It is administered subcutaneously as a biodegradable, controlled-release implant containing 16 mg of ...
Esther S, Kim, Karly P, Garnock-Jones
exaly +3 more sources
Afamelanotide: An Orphan Drug with Potential for Broad Dermatologic Applications
Journal of Drugs in Dermatology, 2021Afamelanotide (SCENESSE®) is a synthetic analogue of α-melanocyte-stimulating hormone that is FDA-approved to increase pain-free sunlight exposure in adult patients with erythropoietic protoporphyria. Its dual photoprotective and anti-inflammatory effects also make it a promising therapy for other photosensitive dermatologic diseases that are
Jessica, Wu, Ronald, Cotliar
exaly +3 more sources
Afamelanotide (CUV1647) in dermal phototoxicity of erythropoietic protoporphyria
Expert Review of Clinical Pharmacology, 2014The application of afamelanotide, an α-melanocyte stimulating hormone agonistic analogue to protoporphyria, a disease with absolute sunlight-intolerance is discussed. The clinics, genetics and existing therapies of protoporphyria are described. The physiological receptor-mediated intracellular signaling of α-melanocyte stimulating hormone and effects ...
Elisabeth I, Minder +1 more
openaire +2 more sources
Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria
British Journal of Dermatology, 2015 In erythropoietic protoporphyria (EPP), an inherited disease of porphyrin-biosynthesis, the accumulation of protoporphyrin in the skin causes severely painful phototoxic reactions. Symptom prevention was impossible until recently when afamelanotide became available.
G, Biolcati +5 more
exaly +3 more sources
Medicaments and oral healthcare. Hyperpigmentation of oral soft tissues due to afamelanotide
Nederlands Tijdschrift voor Tandheelkunde, 2020The medicament afamelanotide is an analogue of endogenous ?-melanocyte-stimulating hormone. It promotes cutaneous pigmentation, providing protection from sunlight. In dermatology, afamelanotide seems to establish therapeutic results for polymorphic light eruption, solar urticaria, erythropoietic protoporphyria, Hailey-Hailey disease, vitiligo and acne ...
C, de Baat +5 more
openaire +2 more sources
Clinical Pharmacokinetics, 2017
Afamelanotide, the first α-melanocyte-stimulating hormone (MSH) analogue, synthesized in 1980, was broadly investigated in all aspects of pigmentation because its activity and stability were higher than the natural hormone. Afamelanotide binds to the melanocortin-1 receptor (MC1R), and MC1R signaling increases melanin synthesis, induces antioxidant ...
Elisabeth I Minder
exaly +3 more sources
Afamelanotide, the first α-melanocyte-stimulating hormone (MSH) analogue, synthesized in 1980, was broadly investigated in all aspects of pigmentation because its activity and stability were higher than the natural hormone. Afamelanotide binds to the melanocortin-1 receptor (MC1R), and MC1R signaling increases melanin synthesis, induces antioxidant ...
Elisabeth I Minder
exaly +3 more sources
Indications and Limitations of Afamelanotide for Treating Vitiligo
JAMA Dermatology, 2015ontheuseofafamelanotideincombinationwithnarrowbandUV-Bfor treating vitiligo. So far, there is no truly satisfactory treat-mentforvitiligo,soanynewapproachismostwelcome.How-ever,thisstudyraisesseveralissues.Afamelanotidebindswiththemelanocortin-1receptor(MC1R),whichisthereceptorup-streamofoneofthekeypathwaysformelanogenesis.
openaire +2 more sources